Tissue Repair Peptides is a recurring topic in our peptide coverage. This hub collects every article tagged Tissue Repair Peptides, newest first, each evidence-graded and tied to real, verifiable sources.
A functional taxonomy of therapeutic and research peptides — 11 classes mapped by molecular target, representative molecules, and evidence maturity, from Grade-A approved drugs to Grade-D marketing claims.
What peptides actually are, how they differ from drugs, hormones and supplements, the major functional classes, and — crucially — what the human evidence does and doesn't support, from Grade-A medicines to Grade C-D research peptides.
The complete alphabetical directory of every peptide in the PeptideVox library — each with its class, highest-confidence evidence grade, and a plain-language summary that keeps human trial data strictly separate from animal, in-vitro and anecdote.
Tendon is the single best-studied musculoskeletal target for repair peptides — yet no human RCT exists for any peptide in any tendinopathy. We rank BPC-157, TB-500/thymosin β-4 and GHK-Cu strictly by the real evidence.
A clinical, evidence-first look at the peptides pitched for rotator-cuff tears, labral injury and shoulder tendinopathy — BPC-157, TB-500/thymosin β-4, and GHK-Cu — and why all three are graded C (preclinical only) for the shoulder.
A clinical, evidence-graded review of the peptides marketed for hamstring pulls, calf and quad strains, and muscle tears — where the animal data are genuinely muscle-specific, and why no completed human trial yet proves any of them heals a strain.
A clinical, evidence-graded review of the peptides marketed for sprains, MCL tears and ACL injury — where the rat data are genuinely ligament-specific, and why no human trial yet proves any of them heals a torn ligament.
A clinical, evidence-first look at the peptides pitched for lateral and medial epicondylitis — BPC-157 and TB-500/thymosin β-4 — and why both are graded C (preclinical only) for the elbow.
A clinical, evidence-ranked look at the peptides marketed for back injury, spinal soft-tissue repair, and disc health — what the published data actually supports, and what is marketing.
An evidence-graded review of the peptides marketed for athletic recovery — BPC-157, ipamorelin, CJC-1295 and TB-500. The honest 2026 verdict: every one is Grade C or D for recovery as an outcome, none is FDA-approved, and all are WADA-banned at all times.
A clinical monograph on Thymosin Beta-4 (Tβ4) — the actin-sequestering repair peptide with a real, decades-long human-trial record in ocular, dermal and cardiac repair. Grade B human evidence, no FDA-approved product, and an unsettled 2026 legal status.
A clinical monograph on Ac-SDKP (goralatide/seraspenide), the N-terminal tetrapeptide fragment of thymosin beta-4. Human chemoprotection data (Grade B), preclinical-only anti-fibrosis, and a WADA-prohibited 2026 status.
A clinical monograph on TB-500 — the synthetic thymosin β4 fragment (Ac-LKKTETQ) marketed for tendon, muscle and tissue repair. Strong preclinical biology, no human efficacy RCT of the fragment, and an unsettled 2026 legal status.
A clinical monograph on Pentadeca Arginate (PDA) — the L-arginine salt of BPC-157 marketed for tendon, gut and wound healing. Zero PDA-specific studies, borrowed preclinical data, and an unsettled 2026 legal status.
A clinical monograph on Pentadeca Arginate — the L-arginine salt of BPC-157. No studies exist under the 'PDA' name; the borrowed parent evidence is 35:1 preclinical, with zero human RCTs and an unsettled 2026 legal status.
A clinical monograph on the arginate (di-L-arginine) salt of BPC-157 — the same peptide with an arginine counterion. The storage and gastric-acid stability advantage is real; the headline oral-bioavailability claims are unproven marketing.
A clinical monograph on BPC-157 — the stable gastric pentadecapeptide marketed for tendon, gut and wound healing. Deep preclinical data, no completed human RCT, and an unsettled 2026 legal status.
Tissue Repair Peptides is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Tissue Repair Peptides, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.